| Followers | 19 |
| Posts | 6174 |
| Boards Moderated | 0 |
| Alias Born | 01/04/2012 |
Tuesday, October 17, 2023 2:31:40 PM
Silvr, I would not be surprised if ANIP/Novitium got the rights to Nuray Chemicals IP related to Tafamidis, and have entered into a collaborative agreement with Pfizer to develop a replacement for a new and improved version of their Vyndamax® (Tafamidis), and Vyndaqel® (tafamidis meglumine) which starts to lose some patents and exclusivity December 2023 through 2024. This will allow Pfizer to switch their patients to the new drug which patent coverage extends to 2041.
Nuray Patent
Samy is the lead inventor for the patent.
Vyndaquel IP expiration
Vyndamax IP expration
FYI, Vyndaquel and Vyndamax accounted for $782 million in revenue for Pfizer in Q2.
JMHO
Nuray Patent
Samy is the lead inventor for the patent.
Vyndaquel IP expiration
Vyndamax IP expration
FYI, Vyndaquel and Vyndamax accounted for $782 million in revenue for Pfizer in Q2.
JMHO
Bullish
Recent ANIP News
- ANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8:00 a.m. ET • GlobeNewswire Inc. • 04/24/2026 10:50:00 AM
- ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity • GlobeNewswire Inc. • 04/20/2026 10:50:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/13/2026 08:40:36 PM
- ANI Pharmaceuticals rolls out generic carbamazepine extended-release capsules • IH Market News • 04/13/2026 03:12:39 PM
- ANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release Capsules • GlobeNewswire Inc. • 04/13/2026 10:50:00 AM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/09/2026 08:14:24 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/09/2026 08:13:29 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/09/2026 08:12:05 PM
- ANI Pharmaceuticals Announces FDA Approval and Launch of Isosorbide Mononitrate Tablet • GlobeNewswire Inc. • 04/08/2026 10:50:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 08:21:22 PM
- ANI Pharmaceuticals Announces Publication of NEW DAY Clinical Trial Results in Ophthalmology • GlobeNewswire Inc. • 04/07/2026 10:50:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/13/2026 09:28:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/13/2026 09:28:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/13/2026 09:28:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/10/2026 08:09:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/10/2026 08:09:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/10/2026 08:07:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/10/2026 08:06:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/10/2026 08:04:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 10:46:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2026 10:22:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 11:46:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 11:45:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 11:01:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 12:05:46 PM
